Manufacturing and support services, for various types of biologics that are manufactured *Roots Analysis* Knowpia

Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly. Presently, a number of service provider companies claim to offer end-to-end solutions, ranging from product development to commercial production, for microbial biologics. Given the obvious advantages of outsourcing, drug developers are likely to continue relying on contract service providers for various aspects of their respective microbial biologic development programs.

To order this 320+ page report, which features 150+ figures and 150+ tables, please visit this - https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html

The USD 9.3 billion (by 2030) financial opportunity within the microbial biomanufacturing market has been analyzed across the following segments:

§ Type of Product

§ API

§ FDF

§ Type of Biologic

§ Proteins

§ Enzymes

§ Growth Hormones

§ Antibody based Drugs

§ Others (plasmid DNA, probiotics, microbiome-based biologics)

§ Type of Microbial Expression System

§ Bacteria

§ Yeast

§ Others (Algae and fungi)

§ Scale of Operation

§ Commercial

§ Preclinical / Clinical

§ Type of End User

§ Small Companies

§ Mid-sized Companies

§ Large / Very Large Companies

§ Key Geographical Regions

§ North America

§ Europe

§ Asia Pacific

§ Middle East and North Africa

§ Latin America

The Microbial Contract Biomanufacturing Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:

§ AGC Biologics

§ Aldevron

§ BioVectra

§ EirGenix

§ Etinpro

§ Eurogentec

§ Northway Biotechpharma

§ Ology Bioservices

§ Porton Biopharma

§ Stelis Biopharma

Table of Contents

1. Preface

2. Executive Summary